An Explorative Study of HRS-2189 Combined With Adebrelimab and BP102 for Metastatic Colorectal Cancer
NCT07061210 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20
Last updated 2025-07-11
Summary
To evaluate the safety and efficacy of HRS-2189 combined with Adebrelimab and BP102 in the treatment of metastatic colorectal cancer
Conditions
- Colorectal Cancer Metastatic
Interventions
- DRUG
-
HRS-2189
HRS-2189
- DRUG
-
Adebrelimab
Adebrelimab
- DRUG
-
BP102
BP102
Sponsors & Collaborators
-
Fudan University
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-07-01
- Primary Completion
- 2026-10-01
- Completion
- 2027-01-01
More Related Trials
-
Apatinib in the Treatment of Metastatic Colorectal Cancer
NCT03403452 ·Status: UNKNOWN ·Phase: PHASE2
-
Second-line Treatment of Metastatic Colorectal Cancer
NCT06242067 ·Status: RECRUITING ·Phase: PHASE2
-
ARQ 197 in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancer
NCT01075048 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Clinical Study of Apatinib Combined With Second - Line Chemotherapy for Metastatic Colorectal Cancer
NCT03412994 ·Status: UNKNOWN ·Phase: PHASE2
-
The Study of JMT101 Combined With Irinotecan as a ≥3rd-Line Treatment in Metastatic Colorectal Cancer
NCT07134205 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
A Prospective Study of MSS-type Metastatic Colorectal Cancer Receiving Multiple Lines of Standard Chemotherapy, Bevacizumab Combined With Adebrelimab
NCT06513221 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Comparison of A140 and Erbitux Combined With mfolfox6 to Evaluate Efficacy and Safety of First-line Treatment for Ras Wild-type mCRC
NCT04835142 ·Status: COMPLETED ·Phase: PHASE3
-
Phase Ⅱ Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC
NCT07003022 ·Status: RECRUITING ·Phase: PHASE2
-
Clinical Study of Irinotecan Liposome (II)-Based Combination Treatment for Irinotecan-resistant Colorectal Cancer.
NCT07044921 ·Status: RECRUITING ·Phase: PHASE2
-
A Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Fruquintinib in the Treatment of Immunodominant pMMR/MSS Metastatic Colorectal Cancer That Has Failed Second-line or Above Treatment
NCT07229872 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Trial of SHR-1210 in Combination With AIN457 in Patients With MSS CRC（SHR-1210-AIN457）
NCT04298320 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Injection of SHR-A1811 Versus Physician Choiced Treatment in Patients With Advanced Colorectal Cancer Who Had Failed to Respond to Oxaliplatin, 5-fu, and Irinotecan
NCT06199973 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study of Brontictuzumab With Chemotherapy for Subjects With Previously Treated Metastatic Colorectal Cancer
NCT03031691 ·Status: COMPLETED ·Phase: PHASE1
-
SHR-A1811 Combined with Apatinib in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer
NCT06666166 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
An Open Label Study Evaluating the Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Participants With Metastatic Colorectal Cancer.
NCT04660812 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Phase II Study of SHR-8068 Injection in Combination With Anti-tumor Therapies in Colorectal Cancer
NCT07071714 ·Status: RECRUITING ·Phase: PHASE2
-
Study of Tumor Tissue Testing in Selecting Treatment for Patients With Metastatic or Locally Advanced Colorectal Cancer
NCT00975897 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.
NCT06060704 ·Status: RECRUITING ·Phase: PHASE2
-
Chidamide in Combination With PD-1 Inhibitor, Bevacizumab, and XELOX for Metastatic Colorectal Cancer
NCT06858969 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Exploratory Study of Irinotecan Liposomes in Maintenance Therapy of Metastatic Colorectal Cancer
NCT06341309 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
Recombinant Anti-tumor and Anti-virus Protein for Injection Plus Xeloda in Treatment of Metastatic Colorectal Cancer
NCT02068131 ·Status: UNKNOWN ·Phase: PHASE2
-
Apatinib in Refractory Colorectal Cancer
NCT03190616 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Efficacy Study of BMS-908662 Alone or in Combination With Cetuximab in Subjects With K-RAS or B-RAF Mutation Positive Advanced or Metastatic Colorectal Cancer
NCT01086267 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer
NCT06341296 ·Status: RECRUITING ·Phase: PHASE2
-
Nivolumab+Ipilimumab+RT in MSS mCRC
NCT04575922 ·Status: UNKNOWN ·Phase: PHASE2